TRIB:NASDAQ 3 forward PE
Why TRIB is my favorite health care buy on NASDAQ:
1) $.12 EPS in last quarter, slowest quarter of year. Should earn $.75 going forward.
2) As noted TRIB manufacturers diagnotic tests (many rapid tests) not drugs. With that said, its TRISTAT (three in one diabetes test) will be submitted to the FDA for CLIA waiver next month (use in doctor's offices) and it already has approval for hospital and clinics. It is the only 3 in 1 test, will be extremely competitive because it entitles the provider to a government subsidy (because it is 3 in 1) and at the last CC it was noted there will be a 65% net on the sales. The market is $500 million worldwide.
Also, their Destiny Max (hardware plus reagents) should be FDA approved in the next 90 days. It is approved in Europe. It replaces old equipment TRIB was selling, is state of the art, and will add revenue.
